July 30, 2016 9:44 PM ET

Diversified Consumer Services

Company Overview of University of Pennsylvania

Company Overview

University of Pennsylvania is an educational institution that offers graduate, undergraduate, professional, summer courses, and distance learning programs in the fields of law, medicines, communication, and dental medicine. The institution was founded in 1740 and is based in Philadelphia, Pennsylvania.

34th and Spruce Streets

Philadelphia, PA 19104

United States

Founded in 1740

Phone:

215-898-5000

Key Executives for University of Pennsylvania

Dean of the School of Design
Executive Vice President
Age: 53
Associate, Licensing and New Business Start-Up at Center for Technology Transfer
Compensation as of Fiscal Year 2016.

University of Pennsylvania Key Developments

BluePen Biomarkers Announces Collaboration with the University of Pennsylvania to Develop Strategic 'Multi-Omics' Platform for Integrated Biomarker Discovery

The University of Pennsylvania has co-founded and structured BluePen Biomarkers in collaboration with Blueprint Bio, Inc. and Emerald Logic, Inc. to conduct biomarker research and identification. BluePen is creating a comprehensive biomarker measurement and discovery pipeline for the acceleration of personalised medicine. BluePen will collaborate with Ian Blair, PhD, the A.N. Richards Professor of Systems Pharmacology and Translational Therapeutics and Director of Center for Cancer Pharmacology in the Perelman School of Medicine at the University of Pennsylvania. BluePen will measure and integrate genomic, proteomic, metabolomic, and lipidomic biomarkers, alongside clinical data, demographics, and other phenotypic data, providing its customers and collaborators with access to a comprehensive 'multi-omics' discoveryplatform. With this collaborative venture, Penn's goal is to radically improve and accelerate the discovery of relevant biomarkers, without bias toward single genes, single modalities, or inappropriate mathematical assumptions.

Biogen Announces Collaboration and Alliance with the University of Pennsylvania to Advance Gene Therapy and Gene Editing Technologies

Biogen announced a broad collaboration and alliance with the University of Pennsylvania to advance gene therapy and gene editing technologies. The research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. Another important aspect of the alliance will focus on validating next-generation gene transfer technology using adeno-associated virus gene delivery vectors. The collaboration will also explore the expanded use of genome editing technology - the insertion, deletion or replacement of DNA in the genome of an organism - as a potential therapeutic platform.

Seres Therapeutics, Inc. Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease

Seres Therapeutics, Inc. announced that it has entered into a multi-year collaboration with leading microbiome clinical-scientists from the University of Pennsylvania (Penn) to support the development of novel treatment approaches for certain rare genetic metabolic diseases including urea cycle disorders, and inflammatory bowel disease (IBD). Under the terms of the agreement, Penn Professors Gary D. Wu, M.D., and James Lewis, M.D., two global leaders in the field of the microbiome, plan to conduct investigator sponsored research evaluating rationally designed bacterial compositions for patients with ulcerative colitis. In a separate study, the Penn team agreed to collaborate with Seres to evaluate the role of the microbiome in certain rare genetic metabolic diseases, beginning with urea cycle disorders. This clinical study is designed to build upon published results suggesting that altering the gut microbiome may reduce toxic levels of ammonia in patients with urea cycle disorders. Findings from these studies are expected to be used in the design of Ecobiotic microbiome therapeutic candidates to interdict in these rare genetic disorders.

Similar Private Companies By Industry

Company Name Region
1-800-Dryclean, LLC United States
1-800-PHONESEX United States
125 Max Drycleaning Center LLC United States
180 Skills LLC United States
19Pencils, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact University of Pennsylvania, please visit www.upenn.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.